Neurotechnology firm Kernel and biopharmaceutical company Cybin announced promising pilot results from a feasibility study of Kernel Flow, a technology that measures brain activity in altered states of consciousness.
Preliminary data from the Cybin-sponsored study suggested that ketamine-induced changes in functional connectivity continued for several days after administration, with headset technology effectively measuring the drug’s neuro-effects over 11 days.
“By utilizing [Kernel] Flow, we will now be able to quantifiably gather real-time functional brain activity during our